AbbVie said it expanded its Board of Directors from twelve directors to thirteen directors on October 14, 2026 and appointed Dr. John M. Carethers as a Class II director.

1. 01

   AbbVie said it expanded its Board of Directors from twelve directors to thirteen directors on October 14, 2026 and appointed Dr. John M. Carethers as a Class II director.

2. 02

   The company said Dr. Carethers currently serves as Vice Chancellor for Health Sciences at the University of California San Diego and was previously a director of Avantor, Inc.

3. 03

   The company said it assigned Dr. Carethers to the Public Policy and Sustainability Committee and that the Board determined he is an independent director under New York Stock Exchange listed company rules, including section 303A.02.

4. 04

   The company said Dr. Carethers may receive independent director compensation disclosed in Exhibit 10.5 to the Form 10-Q for the quarter ended March 31, 2025.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.